Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Checkmate Pharmaceuticals logo — Pioneering advanced immunotherapies to amplify cancer treatm...

Checkmate Pharmaceuticals

Pioneering advanced immunotherapies to amplify cancer treatment options and improve patient outcomes.

Founded 2015 11-50 employees Series C Total: $170.00M Biotechnology, Health and Wellness +2

General Information

Company Name Checkmate Pharmaceuticals
Founded Year 2015
Employees 11-50
Industries Biotechnology, Health and Wellness, Medical Devices +1
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Checkmate Pharmaceuticals. To contact Checkmate Pharmaceuticals, visit checkmatepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2015 and based in Cambridge, Massachusetts. The company's slogan, "Pioneering advanced immunotherapies to amplify cancer treatment options and improve patient outcomes," reflects its core mission. Checkmate Pharma is dedicated to developing innovative cancer immunotherapy solutions using its expertise in CpG oligonucleotides. The company's recent milestone includes an $85.00M Series C investment on 10 June 2020. This investment was led by a group of prominent investors including Novo Holdings, F-Prime Capital, BrightEdge Ventures, Sofinnova Investments, Clough Capital, Decheng Capital, Medicxi Ventures, Moega Funds, Sectoral Asset Management, and VenBio Partners. Checkmate Pharma's clinical programs aim to enable more cancer patients to benefit from advanced immunotherapies by creating immunotherapies that enhance the effectiveness of existing treatments and offer new options for patients and healthcare providers. The company operates within the Biotechnology and Pharmaceutical industries, underlining its commitment to advancing cancer care.

Taxonomy: immunotherapy, cancer treatment, biopharmaceutical, clinical-stage, oncology, CpG oligonucleotides, Cambridge, massachusetts, drug development, cancer care, clinical trials, treatment innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $85.00M 10
Novo Holdings F-Prime Capital Sofinnova Investments
Novo Holdings, F-Prime Capital +8
10 Jun 2020
Venture Round $16.00M -
27 Jan 2020
Series C $22.00M -
12 Dec 2018
Series B $27.00M -
15 Jun 2017
Series A $20.00M -
12 Aug 2015

Checkmate Pharmaceuticals Alternatives & Competitors

View All Alternatives
Checkmate Pharmaceuticals vs
Apollomics
Apollomics United States

We are a biopharmaceutical company committed to the discovery and development of mono- and combinati...

Post-IPO Equity
26 employees
Biotechnology, Health Care
Checkmate Pharmaceuticals vs
Adastra Pharmaceuticals
Adastra Pharmaceuticals United States

Adastra is committed to transforming cancer care.

Venture round
11-50 employees
Biotechnology, Health Care
Checkmate Pharmaceuticals vs
ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc. United States

Overcoming Resistance In Cancer

Post-IPO Equity
119 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Checkmate Pharmaceuticals

Pioneering advanced immunotherapies to amplify cancer treatment options and improve patient outcomes.
Checkmate Pharmaceuticals was founded in 2015.
Checkmate Pharmaceuticals operates in Biotechnology, Health and Wellness, Medical Devices and Pharmaceutical. Its work centres on immunotherapy, cancer treatment, biopharmaceutical and clinical-stage.
Checkmate Pharmaceuticals has approximately 11-50 employees.
Checkmate Pharmaceuticals has completed 5 funding rounds, raising a total of $170.00M. The latest funding stage is Series C.
Top alternatives and competitors to Checkmate Pharmaceuticals include Apollomics, Adastra Pharmaceuticals, ORIC Pharmaceuticals Inc., Cavion, Apexigen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Checkmate Pharmaceuticals and Apollomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Checkmate Pharmaceuticals, https://bouncewatch.com/company/checkmate-pharmaceuticals, updated 27 July 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes